Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer... Show more
EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 32 cases where EXEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EXEL's RSI Indicator exited the oversold zone, of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where EXEL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 283 cases where EXEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on October 07, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on EXEL as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for EXEL turned negative on October 08, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
EXEL moved below its 50-day moving average on October 20, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EXEL crossed bearishly below the 50-day moving average on October 20, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. EXEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.782) is normal, around the industry mean (23.690). P/E Ratio (17.370) is within average values for comparable stocks, (54.778). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (2.163). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (4.688) is also within normal values, averaging (355.294).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
UTEN | 44.85 | 0.09 | +0.21% |
F/m US Treasury 10 Year Note ETF | |||
CADCHF | 0.56 | N/A | N/A |
Canadian Dollar - Switzerland Franc | |||
CNYGBP | 0.10 | N/A | N/A |
China Yuan - United Kingdom Pound | |||
PAUG | 42.60 | N/A | N/A |
Innovator U.S. Equity Power BufferETFAug | |||
ARP | 31.29 | -0.75 | -2.34% |
PMV Adaptive Risk Parity ETF |
A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with JAZZ. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then JAZZ could also see price increases.
Ticker / NAME | Correlation To EXEL | 1D Price Change % | ||
---|---|---|---|---|
EXEL | 100% | +4.60% | ||
JAZZ - EXEL | 35% Loosely correlated | +1.97% | ||
TECH - EXEL | 33% Poorly correlated | +1.47% | ||
MRSN - EXEL | 32% Poorly correlated | -3.55% | ||
ACLX - EXEL | 32% Poorly correlated | -1.33% | ||
ORMP - EXEL | 32% Poorly correlated | +2.18% | ||
More |